Asherson, Philip http://orcid.org/0000-0003-2667-2254
Johansson, Lena
Holland, Rachel
Fahy, Tom
Forester, Andrew
Howitt, Sheila
Lawrie, Stephen
Strang, John
Young, Susan
Landau, Sabine
Thomson, Lindsay
Funding for this research was provided by:
Efficacy and Mechanism Evaluation Programme (14/23/17)
Article History
Received: 25 February 2019
Accepted: 6 September 2019
First Online: 2 December 2019
Ethics approval and consent to participate
: Ethical approval was obtained from the East of England Essex Research Ethics Committee (16/EE/0117). Approvals for the study were further obtained from the Health Research Authority (HRA), the National Offender Management Service (NOMS, England), the Scottish Prison Service (SPS, Scotland), Research and Development from Oxleas NHS Foundation Trust and NHS Forth Valley. All participants provided informed consent and signed approved consent forms for participation in the study.
: Personal identifying data will not be published. Consent was obtained for publication of anonymised group-level data.
: King’s College London departmental research support account received payments for work by PA: consultancy to Shire, Eli Lilly and Novartis; educational/research awards from Shire, Lilly, Novartis, Vifor Pharma, GW Pharmaceuticals and QbTech; speaker at events sponsored by Shire, Lilly, Novartis, Flynn Pharma and Medicen. PA received personal honoaria for talking at events sponsored by Shire, Flynn Pharma and Medicen. SY has received honoraria for consultation and/or educational talks in the last 5 years from Janssen, HB Pharma and/or Shire. She is author of the ADHD Child Evaluation (ACE) and ACE+ for adults and lead author of R&R2 for ADHD Youths and Adults.In the last 3 years, SL has received personal fees from Janssen, Otsuka and Sunovion and research support from Janssen, all in connection with schizophrenia meetings and trials.JS has worked with several pharmaceutical companies to seek to identify new or improved medications, but they do not have a relationship to the study reported here. This has included research grant support and consultancy payments to King’s College London and travelling and/or accommodation and/or conference expenses (including, in the past 3 years, from Martindale, Indivior, MundiPharma, Camurus/Braeburn).The other authors declare that they have no competing interests.